In a filing, AnaptysBio Inc revealed its CEO Faga Daniel unloaded Company’s shares for reported $64268.0 on Mar 25 ’24. In the deal valued at $21.42 per share,3,000 shares were sold. As a result of this transaction, Faga Daniel now holds 749,087 shares worth roughly $14.37 million.
Then, Faga Daniel sold 145,940 shares, generating $3,325,185 in total proceeds. Upon selling the shares at $22.78, the CEO now owns 752,087 shares.
Before that, LOUMEAU ERIC J sold 5,000 shares. AnaptysBio Inc shares valued at $125,000 were divested by the CHIEF LEGAL OFFICER at a price of $25.00 per share. As a result of the transaction, LOUMEAU ERIC J now holds 3,240 shares, worth roughly $62143.2.
Leerink Partners initiated its AnaptysBio Inc [ANAB] rating to an Outperform in a research note published on April 16, 2024; the price target was $47. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in mid April with a ‘”an Overweight”‘ rating. Wedbush also remained covering ANAB and has increased its forecast on March 12, 2024 with a “an Outperform” recommendation from previously “Neutral” rating. BTIG Research started covering the stock on February 26, 2024. It rated ANAB as “a Buy”.
Price Performance Review of ANAB
On Tuesday, AnaptysBio Inc [NASDAQ:ANAB] saw its stock fall -2.44% to $19.18. Over the last five days, the stock has lost -10.12%. AnaptysBio Inc shares have fallen nearly -10.46% since the year began. Nevertheless, the stocks have fallen -15.06% over the past one year. While a 52-week high of $27.50 was reached on 02/26/24, a 52-week low of $13.36 was recorded on 04/19/24. SMA at 50 days reached $23.10, while 200 days put it at $20.07. A total of 0.39 million shares were traded, compared to the trading of 0.14 million shares in the previous session.
Levels Of Support And Resistance For ANAB Stock
The 24-hour chart illustrates a support level at 18.74, which if violated will result in even more drops to 18.30. On the upside, there is a resistance level at 20.05. A further resistance level may holdings at 20.92. The Relative Strength Index (RSI) on the 14-day chart is 37.19, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.63, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.47%. Stochastics %K at 7.49% indicates the stock is a buying.
The most recent change occurred on February 21, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $50 price target.
